Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences (EW) Q2 2025 10-Q highlights
Net sales rose 12% YoY to $1.53 bn, driven by transcatheter valve therapies, lifting 1H revenue to $2.95 bn (+9%). Gross margin slipped 240 bp to 77.5% on mix and higher manufacturing cost, but operating income still advanced 12% to $411 m helped by $21 m of TSA income from the September 2024 Critical Care divestiture. A $47 m impairment on an unexercised acquisition option and a sharply higher tax provision ($64 m vs $20 m) cut continuing-ops net income 8% to $336 m; diluted EPS fell to $0.56 (-8%).
Discontinued operations (Critical Care & one minor product line) logged a $4 m loss vs a $1 m profit last year. Combined, GAAP net income attributable to EW declined 9% to $333 m.
Cash & balance sheet
- Operating cash flow surged 79% YoY to $571 m on working-capital improvements.
- Cash & equivalents climbed to $3.27 bn; total liquidity (cash + ST investments) is $4.06 bn.
- Total liabilities fell 4% to $2.88 bn; net cash position of ~$2.7 bn.
Capital allocation & restructuring
- Repurchased $264 m of stock (-3% share count YoY); treasury stock at cost now $6.46 bn.
- Realignment severance reserve down to $10 m; majority of payments due 2H 25.
Key takeaways: Top-line momentum and robust cash generation underline core valve franchises, while EPS was pressured by non-recurring impairment and taxes. Post-divestiture focus on structural-heart pipeline and optionality from sizeable cash balance remain central to the investment case.
Edwards Lifesciences (EW) – Form 4 insider transaction
Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis’ direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.
The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.
Edwards Lifesciences (EW) – Form 4 insider filing
Corporate Vice President Daniel J. Lippis reported a single transaction dated 07 July 2025. Using transaction code F (shares withheld to cover taxes), 333 shares of common stock were disposed of at an average price of $76.79 per share. Following the tax-related withholding, Lippis’ direct beneficial ownership stands at 26,115.9103 shares.
No derivative securities were reported and no other acquisitions or dispositions were disclosed. The filing notes the routine quarterly purchase activity under the company’s Employee Stock Purchase Plan, but those acquisitions are not itemised in the tables. Given the small size of the tax-related disposition (≈1.3 % of the insider’s holdings) and the absence of open-market sales, the transaction is unlikely to have a material impact on the company’s share supply or insider-ownership sentiment.